Ronda E. Stryker Sells 200,000 Shares of Stryker Corporation (NYSE:SYK) Stock

Key Points

• Ronda E. Stryker, a director at Stryker Corporation, sold 200,000 shares of the company at an average price of $376.45, totaling approximately $75.29 million, reducing her holding by 5.84%.
• Stryker Corporation recently reported $3.13 EPS for the quarter, exceeding analysts' expectations, with a revenue of $6.02 billion, reflecting an 11.1% year-over-year increase.
• The company declared a quarterly dividend of $0.84 per share, scheduled for payment on October 31st, representing an annual yield of 0.9%.

Stryker Corporation (NYSE:SYK - Get Free Report) Director Ronda E. Stryker sold 200,000 shares of the stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the completion of the sale, the director owned 3,222,108 shares of the company's stock, valued at approximately $1,212,962,556.60. The trade was a 5.84% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Stryker Stock Up 0.3%

SYK traded up $1.27 during trading hours on Thursday, reaching $376.21. 1,192,081 shares of the stock traded hands, compared to its average volume of 1,448,662. Stryker Corporation has a fifty-two week low of $320.78 and a fifty-two week high of $406.19. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06. The company has a market cap of $143.83 billion, a price-to-earnings ratio of 49.83, a PEG ratio of 2.77 and a beta of 0.91. The firm's fifty day simple moving average is $387.39 and its two-hundred day simple moving average is $380.33.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.07 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The company had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $5.92 billion. During the same period last year, the firm posted $2.81 EPS. The company's revenue for the quarter was up 11.1% on a year-over-year basis. As a group, analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be given a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 0.9%. Stryker's dividend payout ratio is presently 44.50%.

Analyst Ratings Changes

SYK has been the subject of a number of recent analyst reports. Evercore ISI raised their price target on shares of Stryker from $390.00 to $415.00 and gave the stock an "outperform" rating in a report on Tuesday, July 8th. Needham & Company LLC lifted their price objective on shares of Stryker from $442.00 to $448.00 and gave the stock a "buy" rating in a research report on Friday, August 1st. BTIG Research reissued a "buy" rating on shares of Stryker in a research report on Monday, July 14th. Citigroup restated a "buy" rating and issued a $455.00 price objective (up from $443.00) on shares of Stryker in a research note on Thursday, May 22nd. Finally, Wall Street Zen upgraded shares of Stryker from a "hold" rating to a "buy" rating in a research note on Friday, July 18th. Four analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to MarketBeat.com, Stryker currently has an average rating of "Moderate Buy" and an average target price of $430.10.

Institutional Trading of Stryker

Several hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. grew its stake in shares of Stryker by 1.1% in the 1st quarter. Vanguard Group Inc. now owns 33,059,964 shares of the medical technology company's stock worth $12,306,572,000 after purchasing an additional 361,136 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Stryker by 9.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 12,131,218 shares of the medical technology company's stock valued at $4,515,847,000 after acquiring an additional 1,021,496 shares during the last quarter. Northern Trust Corp lifted its stake in Stryker by 13.2% in the fourth quarter. Northern Trust Corp now owns 3,606,237 shares of the medical technology company's stock valued at $1,298,426,000 after acquiring an additional 420,153 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of Stryker by 13.1% in the first quarter. Goldman Sachs Group Inc. now owns 2,252,895 shares of the medical technology company's stock worth $838,640,000 after buying an additional 261,058 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Stryker by 4.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,086,960 shares of the medical technology company's stock worth $776,871,000 after acquiring an additional 83,954 shares during the period. 77.09% of the stock is currently owned by institutional investors.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.